02 · Clinical Findings
GLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKD
Over five years, a retrospective study linked GLP-1 drug use to fewer end-stage kidney outcomes in adults with CKD and obesity who did not have diabetes.

GLP-1 drug use was linked to fewer end-stage kidney outcomes over five years in adults with CKD and obesity who did not have diabetes.
In a retrospective study with 34,980 patients per group, kidney failure, dialysis or transplantation occurred in 3.3% of treated patients versus 6.0% of controls.
The findings show an association, not causation. Missing kidney health data and differences in access to care may help explain the gap.
Read the full story at Pharmacy Times ↗
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
Combining two diabetes drug classes is not automatically a bigger clinical benefit

At the highest dose, retatrutide cut 21% of body weight in people with type 2 diabetes

Tirzepatide kept nearly 99% of prediabetes patients diabetes-free over three years
